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Abstract
Background: Glycoprotein non-metastatic melanoma protein B (GPNMB)/Osteoactivin (OA) is a transmembrane protein
expressed in approximately 40–75% of breast cancers. GPNMB/OA promotes the migration, invasion and metastasis of
breast cancer cells; it is commonly expressed in basal/triple-negative breast tumors and is associated with shorter
recurrence-free and overall survival times in patients with breast cancer. Thus, GPNMB/OA represents an attractive target for
therapeutic intervention in breast cancer; however, little is known about the functions of GPNMB/OA within the primary
tumor microenvironment.
Methodology/Principal Findings: We have employed mouse and human breast cancer cells to investigate the effects of
GPNMB/OA on tumor growth and angiogenesis. GPNMB/OA-expressing tumors display elevated endothelial recruitment
and reduced apoptosis when compared to vector control-derived tumors. Primary human breast cancers characterized by
high vascular density also display elevated levels of GPNMB/OA when compared to those with low vascular density. Using
immunoblot and ELISA assays, we demonstrate the GPNMB/OA ectodomain is shed from the surface of breast cancer cells.
Transient siRNA-mediated knockdown studies of known sheddases identified ADAM10 as the protease responsible for
GPNMB/OA processing. Finally, we demonstrate that the shed extracellular domain (ECD) of GPNMB/OA can promote
endothelial migration in vitro.
Conclusions/Significance: GPNMB/OA expression promotes tumor growth, which is associated with enhanced endothelial
recruitment. We identify ADAM10 as a sheddase capable of releasing the GPNMB/OA ectodomain from the surface of breast
cancer cells, which induces endothelial cell migration. Thus, ectodomain shedding may serve as a novel mechanism by
which GPNMB/OA promotes angiogenesis in breast cancer.
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Introduction
Glycoprotein non-metastatic melanoma protein B (GPNMB) is
a type I transmembrane protein that is also known as Osteoactivin
(OA), Dendritic Cell–Heparin Integrin Ligand (DC-HIL) or
Hematopoietic Growth Factor Inducible Neurokinin-1 type
(HGFIN). GPNMB/OA is expressed in a wide array of normal
tissue types including: the bone, hematopoietic system and the
skin. Within the bone, GPNMB/OA has been shown to promote
the differentiation of both osteoclasts [1,2] and osteoblasts [3,4].
GPNMB/OA is also readily detectable in immune cells, such as
macrophages and dendritic cells [5,6], and has been shown to
functionally impair T-cell activation [7,8]. Within the skin,
GPNMB/OA has been proposed to be expressed specifically in
melanocytes [9], while others suggest a broader pattern of
expression that includes keratinocytes, melanocytes and Langer-
hans cells [7].
In addition to its diverse roles in normal cells, aberrant
GPNMB/OA expression has been linked to various pathological
disorders such as glaucoma [10], kidney disease [11], osteoarthritis
[12] and several types of cancer, including: uveal melanoma [13],
glioma [14,15], hepatocellular carcinoma [16] and cutaneous
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12093melanoma [17]. Recently, we demonstrated that GPNMB/OA is
highly expressed in several aggressively bone-metastatic sub-
populations of the 4T1 mouse mammary carcinoma cell line.
Moreover, we showed that ectopic expression of GPNMB/OA in
poorly metastatic 66cl4 mouse mammary carcinoma cells is
sufficient to induce MMP-3 expression and increases their invasion
in vitro and promotes bone metastasis in vivo [18]. Subsequently, we
employed IHC-based analysis of tissue microarrays to investigate
the relevance of GPNMB/OA expression in human breast cancer,
and found that GPNMB/OA is expressed in the tumor epithelium
of approximately 10% of human breast cancers and the stromal
compartment of nearly 70% of breast tumors. Moreover,
epithelial, but not stromal, GPNMB/OA expression is a
prognostic indicator of cancer recurrence across all breast cancer
subtypes, and specifically within ‘‘triple negative’’ breast cancers
[19].
GPNMB/OA is localized to diverse subcellular locations within
the cell, including the plasma membrane of cancer cells [17,19],
within melanosomes of melanoma cells [7] and within endocytic/
lysosomal vesicles in osteoclasts [1]. Two GPNMB/OA mRNA
isoforms encoding 560 and 572 amino acid proteins have been
identified; the longer isoform corresponds to a splice variant that
contains an in-frame 12 amino acid insertion within the
extracellular domain [14]. Both isoforms contain a large
extracellular domain (ECD), a single pass transmembrane domain
and a short cytoplasmic tail. The GPNMB/OA ECD contains an
integrin-binding RGD domain that is required for the GPNMB/
OA-dependent adhesive interaction between melanocytes and
keratinocytes [7] and a polycystic kidney disease (PKD) domain
whose function in GPNMB/OA remains unknown. Moreover,
several groups have reported that GPNMB/OA is proteolytically
cleaved in an MMP-dependent manner [9,20,21]. Interestingly,
NIH-3T3 fibroblasts stimulated with a recombinant GPNMB/OA
ECD displayed enhanced Erk and p38 phosphorylation along with
the upregulation of Mmp-3 mRNA [20].
Given the utility of GPNMB/OA expression as a prognostic
indicator of recurrence and its potential as a therapeutic target in
human breast tumors [22,23], we aimed to investigate the
functional role of GPNMB/OA in the primary breast tumor
microenvironment. We demonstrate that GPNMB/OA expres-
sion enhances primary tumor growth, which is associated with
diminished apoptosis and elevated recruitment of endothelial cells.
GPNMB/OA is constitutively shed from breast cancer cells in an
ADAM10-dependent manner and the shed GPNMB/OA ECD is
capable of inducing endothelial cell migration in vitro. Thus, we are
the first to implicate ADAM10 as a sheddase that liberates
GPNMB/OA ECD and to describe a functional role for the
GPNMB/OA ECD in promoting endothelial cell migration.
Results
Ectopic GPNMB/OA expression enhances primary tumor
growth
Previously we have reported that GPNMB/OA expression is
increased in in vivo selected aggressively bone metastatic subpop-
ulations of 4T1 mammary carcinoma cells [18]. In addition to
bone metastatic sub-populations (592, 593), GPNMB/OA is also
overexpressed in 4T1 sub-populations that are either aggressively
metastatic to lung (526), liver (2776, 2792) or that have been
explanted from primary tumors (066) (Figure 1A). This is
consistent with our previous observations that GPNMB/OA is
also overexpressed in human breast tumors, and suggests that
GPNMB/OA may be functionally implicated in regulating tumor
growth in addition to promoting invasion and metastasis [18,19].
To investigate this hypothesis, we employed an independent, less
aggressive mammary tumor cell line in which we generated one
pooled vector control (VC), and two clonal populations (GPNMB/
OA4, GPNMB/OA5) of 66cl4 mouse mammary carcinoma cells.
Variable levels of GPNMB/OA protein could be detected in the
cell lysates of 66cl4-OA4 and 66cl4-OA5 cells (Figure 1B). To
assess the consequences of GPNMB/OA expression on primary
mammary tumor growth, 66cl4 cells were injected into the
mammary fat pads of Balb/c mice. GPNMB/OA increased the
incidence of mammary tumor formation (Figure 1C) and also
accelerated tumor outgrowth relative to VC tumors (Figure 1D).
Moreover, the kinetics of tumor outgrowth correlated with the
level of GPNMB/OA expressed in these cells (Figure 1B, D). To
rule out the possibility that these findings reflect phenotypes
associated with clonal breast cancer populations, we generated a
population of pooled GPNMB/OA expressing cells (Supple-
mental Figure S1A) and found that these too enhanced tumor
growth relative to vector control cells (Supplemental Figure
S1B).
GPNMB/OA expressed on antigen presenting cells can
suppress T-cell activation [7,8,24]. Recently, it has been shown
that GPNMB/OA expressed in melanoma cells promotes their
growth by impairing the activation of melanoma-reactive T-cells
[25]. To assess whether a similar mechanism could account for
GPNMB/OA-induced mammary tumor growth observed in
Balb/c mice, we performed a second set of mammary fat pad
injections into athymic mice that lack functional T-cells.
Importantly, the GPNMB/OA-associated increase in tumor
outgrowth observed in Balb/c mice was maintained even when
cells were injected into immunodeficient mice, although to a lesser
degree when compared to injections performed in Balb/c mice
(Supplemental Figure S1B). Thus, the tumor growth promot-
ing effects of GPNMB/OA cannot be fully explained through a
mechanism involving suppression of T-cell activation.
GPNMB/OA expression in breast cancer cells is associated
with decreased apoptosis and increased vascular density
in vivo
To better characterize the functional role of GPNMB/OA in
promoting tumor growth, we removed the primary tumors and
subjected them to IHC analysis to assess differences in prolifer-
ation, apoptosis and angiogenesis. Using antibodies against Ki67
as a proliferation marker [26], we observed no significant
differences in the mean percentage of proliferation control
(28.7%) versus GPNMB/OA-expressing mammary tumors
(25.1%) (Figure 2A). We next quantified the number of apoptotic
cells in non-necrotic regions of these mammary tumors and found
that, on average, fewer cells in GPNMB/OA-expressing tumors
(1.1%) were undergoing apoptosis when compared to control
mammary tumors (2.6%) (Figure 2B). Finally, we assessed the
vascular density of these tumors by quantifying the degree of
CD31 positivity, a routinely used endothelial cell marker. These
analyses revealed that the vascular density in GPNMB/OA-
expressing mammary tumors (3.5%) was significantly higher when
compared to control tumors (0.9%) (Figure 2C). We next
investigated whether this increase in angiogenesis could be
attributed to VEGF induction by GPNMB/OA. Similar quantities
of VEGF were detected in cell lysates and conditioned media from
vector control and GPNMB/OA expressing 66cl4 cells (Supple-
mental Figure S2 A, B); however, tumors derived from
GPNMB/OA expressing cells (mean 652ng/ml) produced nearly
twice as much VEGF as vector control tumors (mean=328 ng/
mL), suggesting that GPNMB/OA may indirectly upregulate
GPNMB and Tumor Angiogenesis
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microenvironment (Supplemental Figure S2C).
To address whether the GPNMB/OA-associated angiogenic
phenotype was specific to the 66cl4 mouse mammary tumor
model, we next interrogated the association between GPNMB/
OA expression and vascular density in human breast cancer cells
and primary tumors. We ectopically expressed GPNMB/OA in
BT549 cells, a basal breast cancer model. Although vector control
and GPNMB/OA-expressing BT549 cells were incapable of
forming tumors when injected into athymic mice (data not shown),
we analyzed whether GPNMB/OA is capable of enhancing the
angiogenic phenotype of these cells by performing matrigel plug
assays. Matrigel plugs containing either vector control or
GPNMB/OA-expressing BT549 cells were harvested 10 days
post-injection and subjected to immunohistocytochemical analysis
for CD31 expression. These analyses, in agreement with our
results from GPNMB/OA-expressing 66cl4 mouse mammary
tumors, revealed that matrigel plugs containing GPNMB/OA-
expressing BT549 cells displayed greater endothelial recruitment
(11.8%) when compared to matrigel plugs composed of empty
vector control cells (8.5%) (Supplemental Figure S3A, B).
We next interrogated gene expression data from laser capture
microdissected tumor epithelium isolated from breast tumors that
were categorized as high versus low MVD, based on quantification
of CD31 staining [27] (Figure 3A). Interestingly, we observed a 2-
fold increase in GPNMB/OA mRNA levels in the epithelium of
breast tumors characterized as high MVD (average expression
value=1.452) versus those with low MVD (average expression
value=0.734) (Figure 3B). These data, together with our
observations from our mouse and human breast cancer models,
suggest a role for GPNMB/OA in promoting endothelial
recruitment during mammary tumorigenesis.
GPNMB/OA extracellular domain is shed by ADAM10
It has been previously reported that GPNMB/OA can be
cleaved and shed from the cell surface, producing an ECD
fragment that has signaling capacity in stromal cells [20,21]. The
GPNMB/OA ECD, when fused to the immunoglobulin Fc region,
is also capable of binding to the surface of endothelial cells [28].
Given these observations, we hypothesized that the shed, soluble
fragment of GPNMB/OA might facilitate the GPNMB/OA-
dependent pro-angiogenic phenotype. To investigate this hypoth-
Figure 1. GPNMB/OA enhances primary tumor growth. (A) Immunoblot analysis of GPNMB/OA expression in parental cells (4T1) and explants
taken from primary tumors (066, 067) and the following metastatic sites: bone (592, 593), lung (526, 533) and liver (2776, 2792). (B) Expression of
GPNMB/OA was confirmed by immunoblot analysis of total cell lysates from vector control (VC) and two clonal cell lines expressing GPNMB/OA
(GPNMB/OA4 and GPNMB/OA5). As a loading control, total cell lysates were blotted for a-Tubulin (A, B). (C) Percentage of Balb/c mice that
developed mammary tumors reaching 200mm
3 by 6 weeks post-injection of VC (n=13/30), GPNMB/OA4 (n=20/28) or GPNMB/OA5 (n=6/10)
expressing 66cl4 cells. (D) Tumor growth curves in mice injected with VC (n=13), GPNMB/OA4 (n=20) and GPNMB/OA5 (n=6) expressing 66cl4 cells.
doi:10.1371/journal.pone.0012093.g001
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consistently shed into the conditioned media of breast cancer
cells. Indeed, we can detect a soluble form of GPNMB/OA in
conditioned media from GPNMB/OA-expressing 66cl4 cells
(Figure 4A). To extend these observations to a human breast
cancer model, we engineered two cell lines overexpressing
GPNMB/OA. Full length GPNMB/OA, containing a C-terminal
V5-epitope tag, was readily detectable in the basal-like BT549
breast cancer cells and luminal-like MDA-MB-453 cells engi-
neered to overexpress this protein (Figure 4B). In addition to full
length GPNMB/OA, we also identified two small C-terminal
fragments with molecular weights of approximately ,25kDa and
,13kDa, which we labeled CTF1 and CTF2, respectively
(Figure 4B). These fragments are products of post-translational
proteolytic processing and have previously been described in
C2C12 myoblast cells engineered to overexpress GPNMB/OA, as
well as in melanocytes and melanoma cells endogenously
expressing GPNMB/OA [9,20]. Notably, processing of
GPNMB/OA was less efficient in MDA-MB-453 cells relative to
that observed in BT549 cells, despite comparable expression levels
of the full length protein in both cell lines (Figure 4B). In
addition, we observed that less GPNMB/OA ECD was shed into
Figure 2. Osteoactivin inhibits apoptosis and enhances angiogenesis in 66cl4-derived mammary tumors. Tumors derived from vector
control or Osteoactivin-expressing 66cl4 cells were characterized using immunohistochemical analysis for (A) proliferation (Ki67), (B) apoptosis
(TUNEL) and (C) vascular density (CD31). Representative images are shown for control tumors (VC) or GPNMB/OA5-expressing tumors (left panels).
Proliferation and apoptosis are expressed as the percentage of Ki67 or TUNEL-positive nuclei/field, respectively. Vascular density is expressed as the
percentage of total CD31-positive pixels/field.
doi:10.1371/journal.pone.0012093.g002
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conditioned media harvested from BT549 cells (Figure 4C).
The mechanism governing GPNMB/OA shedding has been the
subject of growing interest, yet the specific proteases involved in
this process have yet to be elucidated. The ADAM (A Disintegrin
And Metalloproteinase) subfamily of matrix metalloproteinases
(MMPs), known for their sheddase abilities, have been recently
postulated to be candidate proteases that could mediate GPNMB/
OA ectodomain shedding [9]. To test this possibility, we first
investigated whether ADAM10, 12 or 17 were differentially
expressed between BT549 and MDA-MB-453 cells, which differ in
their degree of GPNMB/OA shedding. We found that both
ADAM10 and ADAM17 were expressed at higher levels in BT549
cells compared to MDA-MB-453 cells, whereas ADAM12
expression was higher in MDA-MB-453 cells (Figure 5A). We
next asked whether ADAM10 or ADAM17 - which are the
primary sheddases for most ectodomains [29] - were functionally
required for GPNMB/OA shedding. To accomplish this, we
performed transient siRNA mediated knockdown of ADAM10
and ADAM17, independently or in combination, in GPNMB/
OA-expressing BT549 cells and found that the amount of the
GPNMB/OA ECD detectable in the conditioned media was
diminished only when ADAM10 expression was reduced
(Figure 5B, upper panels). Moreover, co-suppression of
ADAM17 and ADAM10 did not further diminish release of the
soluble GPNMB/OA ECD. Immunoblots for GPI were per-
formed to control for the total amount of protein in the condition
media (Figure 5B, upper panels). Immunoblots for ADAM10
and ADAM17 revealed that the siRNA-mediated knock-down of
these proteins was effective (Figure 5B, lower panels). To
confirm whether ADAM10 was required for GPNMB/OA
shedding in an independent cell line, we chose the basal-like
MDA-MB-468 cell line that endogenously expresses GPNMB/
OA. Indeed, transient siRNA-mediated knockdown of ADAM10
in these cells also greatly diminished shedding of the GPNMB/OA
ECD into the culture media (Figure 5C). Together, these data
indicate that ADAM10 is able to release the GPNMB/OA
ectodomain from the surface of breast cancer cells.
GPNMB/OA ECD promotes endothelial cell migration
Having determined that GPNMB/OA is constitutively shed in
an ADAM10-dependent manner in our breast cancer model
systems, we next investigated whether this shed GPNMB/OA
ECD possessed angiogenic properties. Given that the migration of
endothelial cells is a requisite step during tumor angiogenesis, we
investigated whether the GPNMB/OA ECD was capable of
promoting this process. First, we collected conditioned media
(CM) from empty vector control (VC) or GPNMB/OA-expressing
BT549 cells and used this as chemoattractant for HPMEC
endothelial cells in vitro. We found that CM from VC cells induced
limited endothelial migration; however, this increase did not
achieve statistical significance when compared to the effects of
serum free media (DMEM) (Figure 6A). In contrast, CM from
GPNMB/OA-expressing BT549 cells induced a .2-fold enhance-
ment in endothelial migration when compared to serum free
media (Figure 6A). To determine whether this effect on
endothelial migration was specific to shed GPNMB/OA, we used
a V5-tagged recombinant protein encoding only the ECD of
GPNMB/OA (rhECD). In this assay, known inducers of
endothelial migration such as FGF-2 and VEGF, promoted a
.2 fold or 1.5 fold increase in endothelial migration, respectively,
when compared to serum free media (DMEM) (Figure 6B). By
comparison, we found that recombinant human GPNMB/OA
ECD induced a 1.5-fold increase in endothelial migration
compared to serum free media (Figure 6B). Together, these
observations support the hypothesis that shed GPNMB/OA
augments breast tumor angiogenesis by directly stimulating
endothelial migration.
Discussion
We have previously demonstrated that GPNMB/OA expres-
sion is elevated during the formation of primary mammary
tumors; its expression is further elevated in breast cancer bone
metastases and plays a functional role in this process [18].
GPNMB/OA belongs to a group of osteomimetic proteins (ie.
Osteopontin, Osteonectin and Osteocalcin) [30] that are normally
expressed by osteoblasts/osteoclasts, which when expressed in
cancer cells, promote the development of bone metastases. Indeed,
GPNMB/OA is emerging as a critical mediator of osteoblast and
osteoclast differentiation, two cell types important for bone
remodeling and turnover [2,3,4]. In addition, GPNMB/OA
expression is up-regulated in bone pathologies such as osteoar-
thritis and during fracture repair [12,31]. However, in the current
study, we demonstrate that GPNMB/OA expression is also
elevated in 4T1 subpopulations that preferentially metastasize to
lung and liver, in addition to those that spread to bone. This data
suggests that the GPNMB/OA may play a more generalized role
in promoting tumor progression, but does not preclude the
possibility that certain GPNMB/OA-related functions specifically
favor the development of bone metastases.
Figure 3. GPNMB/OA-expressing human mammary tumors display enhanced vascular density. (A) Human breast tumors were stained
with CD31 and classified into two groups, those with low or high microvascular density (MVD). (B) Laser capture microdissection was used to extract
RNA specifically from the tumor epithelium of low or high MVD breast tumors. Analysis of GPNMB/OA mRNA expression values for each tumor
revealed a significant correlation between high levels of GPNMB/OA expression in the tumor epithelium and high microvascular density. *, P=0.008,
Student’s t-test.
doi:10.1371/journal.pone.0012093.g003
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66cl4 mouse mammary carcinoma cells, GPNMB/OA expression
can enhance tumor growth in vivo. Our data suggests that
GPNMB/OA-dependent augmentation of tumor growth is
attributed to decreased apoptosis and increased angiogenesis in
GPNMB/OA expressing tumors. It is not clear whether the
predominant tumor growth stimulatory effect of GPNMB/OA
stems from impaired apoptosis or enhanced vascular recruitment;
however, it is likely that the two processes are interrelated. Indeed,
breast cancer cells that overexpress GPNMB/OA, when grown in
complete media, tend to display slower in vitro growth rates when
compared to empty vector control cells [19], suggesting that the
reduced apoptosis observed in GPNMB/OA-expressing mamma-
ry tumors may be secondary to tumor/stromal interactions that
occur only in vivo. Recently, an alternate mechanism, involving
GPNMB/OA-mediated suppression of T-cell activation, has been
proposed to explain how GPNMB/OA can promote the growth of
melanoma tumors [25]. In this study, shRNA mediated reduction
in GPNMB/OA expression in B16 melanoma cells was shown to
cause a reduction in sub-cutaneous tumor growth compared to
control cells when injected into syngeneic mice. Interestingly, this
difference in melanoma growth between GPNMB/OA-expressing
cells and those with the GPNMB/OA knockdown was not
observed when these cells were injected into immunodeficient
mice [25]. The mechanism by which GPNMB/OA promoted
melanoma tumor outgrowth was through suppression of T-cell
activation, which normally serves to limit tumor outgrowth [25].
Given that we employed a syngeneic mouse breast cancer model
to initiate our studies, we examined this possibility and found that
GPNMB/OA expression was able to promote the growth of 66cl4
cells in both an immunocompetent and immunocompromised
background. These observations indicate that GPNMB/OA can
contribute to tumor growth through mechanisms other than
suppression of anti-tumor immunity.
The observation that primary human breast tumors with high
MVD express elevated levels of GPNMB/OA in the tumor
epithelium provides a clinical correlate that substantiates our in vivo
studies with the 66cl4 mammary carcinoma model. Importantly,
we restricted these analysis to examining GPNMB/OA expression
in the tumor epithelium of high and low MVD primary breast
tumors; therefore, it remains to be determined whether GPNMB/
OA expression in the tumor stroma is also associated with
enhanced angiogenesis. Of interest is the observation that tumor–
derived endothelial cells express high levels of GPNMB/OA
relative to endothelial cells derived from normal tissues [32].
However, it is unclear whether GPNMB/OA expressed within
endothelial cells functions to promote angiogenesis. Our data
suggests that GPNMB/OA, when expressed in breast cancer cells,
can increase vascular recruitment and enhance tumor growth.
Interestingly, VEGF levels in GPNMB/OA expressing 66cl4
cells is similar to empty vector control cells when measured in vitro;
Figure 4. The GPNMB/OA ectodomain is shed from breast
cancer cells. (A) The shed form of GPNMB/OA was detected in the
conditioned media from 66cl4 cells engineered to overexpress this
protein. AMF/GPI is a secreted cytokine that served as a loading control
for the conditioned media collected from VC, GPNMB/OA4 and GPNMB/
OA5-expressing cells (B) Anti-V5 immunoblot identified full length
GPNMB/OA as well two C-terminal fragments (CTF1 and CTF2) in human
breast cancer cells engineered to overexpress GPNMB/OA (BT549-WT
and MDA-MB-453-WT). Breast cancer cells harboring an empty vector
(VC) served as negative controls. Immunoblots for a-Tubulin were
performed to control for protein loading in whole cell lysates. (C)
Immunoblot analysis with an antibody directed to the extracellular
domain of GPNMB/OA identified shed GPNMB/OA in the conditioned
media (CM) harvested from GPNMB/OA-expressing BT549 cells (WCL:
whole cell lysate).
doi:10.1371/journal.pone.0012093.g004
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OA-expressing compared to VC mammary tumors. Given that
GPNMB/OA is only capable of inducing VEGF expression in vivo,
it is likely that GPNMB/OA promotes interactions with and/or
recruitment of stromal cells, which in turn produce increased
amounts of VEGF. Potential stromal cell types that could be
involved in this process are tumor-associated macrophages
(TAMs). These cells are actively recruited into breast tumors
and are known to produce VEGF, which contributes to
angiogenesis and breast tumor growth [33]. Whether GPNMB/
OA-expressing mammary tumors are characterized by increased
numbers of infiltrating TAMs requires further investigation.
In addition to its ability to indirectly upregulate VEGF in vivo,
we investigated whether GPNMB/OA may be able to promote
angiogenesis via direct interactions with endothelial cells. Recent
studies demonstrating that GPNMB/OA can undergo proteolytic
processing led us to investigate the possibility that this protein was
subject to ectodomain shedding in breast cancer cells. We are the
first to identify ADAM10 as specific protease capable of cleaving
and releasing the ECD of GPNMB/OA. This observation is
consistent with published reports showing that GPNMB/OA
shedding can be inhibited by GM6001, a broad spectrum MMP-
inhibitor [9,20,21]. GPNMB/OA processing can also be induced
through the use of a calmodulin inhibitor or via PMA stimulation
[9]. It has been proposed that ADAM10 can promote the
constitutive shedding of target proteins, such as CD44, whereas
PMA-induced CD44 shedding is mediated through ADAM17
[34]. In our study, we specifically investigated whether ADAM10
and ADAM17 were responsible for constitutive shedding of
GPNMB/OA in breast cancer cells, thus it is possible that
ADAM17 is also capable of shedding GPNMB/OA in the context
of PMA stimulation.
Our data indicate that the soluble extracellular domain of
GPNMB/OA can function as a chemoattractant for endothelial
Figure 5. ADAM10 induces shedding of the GPNMB/OA ectodomain. (A) Immunoblot analysis of ADAM10, ADAM12 and ADAM17
expression in BT549 and MDA-MB-453 cells. Arrow indicates band corresponding to Adam17 and asterisk denotes a doublet of non-specific bands.
(B) siRNA-mediated knockdown of ADAM10, but not ADAM17, reduced shedding of GPNMB/OA in BT549 cells. Upper panels, immunoblot analysis for
GPNMB/OA in the CM harvested from BT549-GPNMB/OA cells treated with the indicated control and ADAM-specific siRNAs. Lower panels,
immunoblot analysis was performed to determine the degree of ADAM10 and ADAM17 knockdown. Arrow indicates band corresponding to Adam17
and asterisk denotes a doublet of non-specific bands. (C) A role for ADAM10 in GPNMB/OA ectodomain shedding is confirmed in MDA-MB-468
human breast cancer cells that endogenously express GPNMB/OA. An immunoblot for GPNMB/OA was performed on CM harvested from MDA-MB-
468 breast cancer cells treated with control or ADAM10-specific siRNAs. Immunoblot analysis with antibodies specific for ADAM10 was performed to
confirm knockdown of ADAM10 expression. Immunoblots for a-Tubulin were performed to control for protein loading in whole cell lysates (A, B, and
C). Immunoblots for AMF/GPI were performed to control for protein loading in the CM samples (B, C). CM refers to conditioned media, Lysate
indicates whole cell lysates prepared from these cells.
doi:10.1371/journal.pone.0012093.g005
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While the receptor for the GPNMB/OA ECD in endothelial cells
is not known, the literature implicates a number of interesting
candidates. For example, GPNMB/OA can be immunoprecip-
itated with either integrin b1o ri n t e g r i nb3 in differentiating
osteoclasts [2]. Presumably this interaction occurs via the N-
terminal RGD domain in GPNMB/OA, which is functionally
required for its ability to adhere to endothelial cells [2]. An
increasing body of evidence supports a role for the b1c l a s so f
integrins in regulating endothelial adhesion, migration and
survival during tumor induced angiogenesis [35]. The b3
integrin, as part of the aVb3 receptor, is expressed on the
surface of endothelial cells during angiogenesis and has been
reported to interact with and potentiate FGF-2 signaling in
endothelial cells [36]. Thus, integrins may serve as receptors for
the GPNMB/OA ECD and transduce signals that promote
endothelial migration.
The effects of GPNMB/OA rhECD on endothelial migration
are significant but more modest than the effects of CM containing
shed GPNMB/OA ECD, suggesting that GPNMB/OA cooper-
ates with other factors to promote endothelial migration and
angiogenesis. It is conceivable that the shed form of GPNMB/OA
can act directly to induce endothelial migration, which in concert
with an indirect upregulation of VEGF, leads to a robust
angiogenic response.
Given the growing interest in GPNMB/OA targeted agents in
breast cancer [22,23], our observations that ADAM10 functions as
a sheddase for GPNMB/OA have potentially important thera-
peutic implications. CDX-011 is an anti-GPNMB/OA antibody-
drug conjugate whose efficacy is proportional to the levels of cell
surface GPNMB/OA expressed on cancer cells [19,21]. Thus,
GPNMB/OA shedding from the cell surface may limit the efficacy
of GPNMB/OA-targeted therapies. It is possible that agents such
as CDX-011 might be improved when used in combination with
ADAM10 inhibitors that would reduce ECD shedding of
GPNMB/OA. One such inhibitor, INCB7839, has been shown
to cooperate with receptor tyrosine kinase inhibitors that target
EGFR and ErbB2 to impair breast tumor growth [37]. Similarly,
epirubicin, a chemotherapeutic drug known to down-regulate
ADAM10 expression in cancer cells [38], when used in
combination with CDX-011, could potentially enhance its
efficacy.
Figure 6. GPNMB/OA ECD promotes endothelial migration. (A) Human pulmonary microvascular endothelial cells (HPMECs) were plated onto
the upper well and allowed to migrate towards serum free media (DMEM) or conditioned media (CM) harvested from vector control (VC) or GPNMB/
OA-expressing cells (GPNMB/OA). The area in square pixels was quantified over fifteen images for each condition (left panel), one representative field
for each condition is shown (right panel). The data is the average of three independent experiments performed in triplicate and the standard error is
shown: *; P,0.006; **; P,0.0007. (B) HPMECs were plated in the upper chamber and allowed to migrate towards serum free media containing
recombinant FGF2 (50 ng/ml), VEGF (50 ng/ml) or GPNMB/OA (rhECD, 100ng/ml). Quantification (left panel) was performed as described in (A) and
one representative field for each condition is shown (right panel). The data is the average of three independent experiments performed in triplicate.
The standard error is shown. All P-values were determined by t-test, comparing the experimental condition to untreated control: *, P=0.0014; **,
P=0.0138; #, P=0.0005).
doi:10.1371/journal.pone.0012093.g006
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Ethics Statement
Studies involving laser capture microdissection of human breast
tumor samples and subsequent gene expression analysis were
approved by the McGill University Health Centre Research Ethics
Board (Protocols SUR-99-780 and SUR-00-966). All patients
provided written, informed consent.
For experiments requiring animal use, the mice were housed in
facilities managed by the McGill University Animal Resources
Centre and all animal experiments were conducted under a
McGill University approved Animal Use Protocol (#4830) in
accordance with guidelines established by the Canadian Council
on Animal Care.
Cell culture and transfections
The murine 4T1 and human BT549, MDA-MB-453 and
MDA-MB-468 breast cancer cell lines used in this study were
obtained from the ATCC and cultured according to their
guidelines. The 66cl4 murine mammary carcinoma cells were a
generous gift from Dr. Fred Miller (Barbara Ann Karmanos
Cancer Institute, Detroit, MI). All 4T1-derived subpopulations
were generated by in vivo selection in our lab [18; Tabarie `s and
Siegel, unpublished data]. Human pulmonary microvascular
endothelial cells (HPMEC-ST1-6R) have been described previ-
ously [39] and were a generous gift from Dr. Vera Krump-
Konvalinkova (IPEK-LMU, Munich, Germany). The pEF1-
GPNMB/OA vector was constructed by ligating the full-length
human GPNMB/OA cDNA (Open Biosystems; Accession:
BC032783) into a pEF1/V5-His expression vector (Invitrogen)
using 59 Eco RI and 39 Not I restriction enzyme sites. BT549 and
MDA-MB-453 cell lines were engineered to express GPNMB/OA
by LipofectAMINE 2000 (Invitrogen)–mediated transfection.
GPNMB/OA-expressing BT549 cells are pools of 3 independent
clones. Osteoactivin-expressing 66cl4 cells have been described
previously [18]. Transient knockdown of ADAM10 and ADAM17
was accomplished by transfection (Lipofectamine 2000, Invitro-
gen) using 15 nM of the ON-TARGETplus SMARTpool [pool of
four ADAM10 or ADAM17-targeted small interfering RNAs
(siRNA), Dharmacon]. An ON-TARGETplus pool of four non-
targeting (scrambled) siRNAs was used as a control. Twenty-four
hours later the transfection media was removed, the cells were
washed once with PBS and media was changed to serum free
media (SFM). Conditioned media, used for immunoblot or ELISA
analysis, was collected after 48 hours.
Immunoblotting
Sub-confluent cells were lysed for 20 min. on ice in TNE lysis
buffer. Protein concentrations were determined by Bradford assay
(Bio-Rad) and 30–45 mg of total protein were used in gel
electrophoresis. For immunoblotting of conditioned media (CM),
1mL of CM was concentrated using microcentricon tubes (30kDa
MWCO, Millipore) and 10uL of protein the concentrate was
loaded on a gel. The antibodies used were as follows: GPNMB/
OA (1:2,500 dilution; R&D Systems), Osteoactivin (1:2,500
dilution; R&D Systems), ADAM10 (1:1,000 dilution; Millipore),
ADAM17 (1:1,000 dilution; Millipore), ADAM12 (1:200 dilution;
rb122) [40], GPI (1:1,000 dilution; Santa Cruz), V5 (1:5,000
dilution, Sigma) and a-Tubulin (1:10,000 dilution; Sigma-Aldrich).
Appropriate horseradish peroxidase–conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories) were used at a
dilution of 1:10,000 and proteins were visualized by chemilumi-
nescence (Millipore).
In vivo tumor growth assays
Female Balb/c mice (4–6 weeks) were purchased from Charles
River Laboratories (Wilmington, MA). For the tumor growth
assays, 66cl4 mammary carcinoma cells were harvested from sub-
confluent plates, washed once with PBS and resuspended (10
4
cells) in 50ml of a 50:50 solution of matrigel (BD Biosciences) and
PBS. This cell suspension was injected into the right abdominal
mammary fat pad of Balb/c mice and measurements were taken
beginning on day 10 post injection for the time periods indicated.
Tumor volumes were calculated using the following formula:
pLW
2/6, where L is the length and W is the width of the tumor.
Tumors were surgically removed, using a cautery unit, once they
reached a volume between 200–300 mm
3.
Matrigel plug assays
Female athymic mice (4–6 weeks) were purchased from Charles
River Laboratories (Wilmington, MA). Subconfluent BT549 cells
were trypsinized, washed once in PBS and resuspended at a final
concentration of 1610
7 cells/mL in matrigel. A 100mL cell
suspension was injected subcutaneously into athymic mice. Mice
were sacrificed and matrigel plugs were removed 10 days post-
injection. The matrigel plugs were then fixed overnight in 4%
paraformaldehyde and prepared for immunohistocytochemical
staining.
Immunohistocytochemical staining and analysis of 66cl4
mammary tumors
Primary mammary tumors were fixed overnight in 4%
paraformaldehyde. Immunohisto-cytochemistry was performed
with the following antibodies: Ki67 (1:100 dilution; BD Pharmin-
gen; Mississauga, ON) and CD31 (1:200 dilution; BD Pharmin-
gen). Appropriate Biotin-SP-conjugated anti-IgG secondary anti-
bodies were purchased from Jackson Laboratories (Bar Harbor,
ME). Apoptotic cells were detected using an ApopTagH Peroxi-
dase In Situ Apoptosis Detection Kit (ChemiconH International;
Temecula, CA) in accordance with the manufacturer’s instruc-
tions. Sections were developed with 3-3-diaminobenzidine-tetra-
hydrochloride and counterstained with hematoxylin. Slides were
first scanned using a Scanscope XT digital slide scanner (Aperio,
Vista, CA, USA) and further analyzed with Imagescope software
(Aperio) using either positive pixel count or immunohistocyto-
chemistry nuclear algorithms. For Ki67 and TUNEL staining,
data was represented as a percentage of positive nuclei among
total nuclei in each field. For CD31 analyses only moderate (+2)
and strong (+3) staining were considered positive. The number of
positive pixels is represented as a percentage of total pixels per field
(66cl4 tumors) or as CD31-positive pixels per nuclei (BT549
plugs).
Assessment of GPNMB/OA expression and MVD in
human breast tumors
Immunohistocytochemistry directed against PECAM1 (Cat.
No. BBA7, R&D Systems, Minneapolis, MN) was performed for
MVD quantitation according to antibody manufacturer’s instruc-
tions. Quantitation of PECAM1 staining density was performed by
averaging the stained pixel intensity of 3 fields captured at 106
magnification using imageJ (http://rsb.info.nih.gov/ij/). Tissue
samples from 21 patients undergoing surgery for primary invasive
ductal carcinoma (IDC) with no prior neoadjuvant therapy were
subjected to Laser Capture Microdissection (LCM); these were
selected from more than 100 tumors based on their having the
highest and lowest MVD. From this cohort we obtained 17
samples of tumor-associated vasculature. LCM, RNA isolation
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carried out as previously described [27,41]. Microarray data were
extracted and analyzed as previously described [27]. Normalized
GPNMB/OA expression values were determined from the
following Agilent probe: A_23_P134426. To minimize the effect
of outliers in this small subset of tumors, we removed the tumors
with highest and lowest GPNMB/OA expression from both
groups (high MVD and low MVD). This resulted in the following
sample sizes low MVD (n=7) and high MVD (n=8). Student’s T-
test (2 tails) was used to assess statistical significance.
Quantification of shed GPNMB/OA and soluble VEGF
The GPNMB/OA ELISA assay was designed by coating 96-
well plates with capture antibody (human anti-GPNMB/OA,
2.10.2), which was generously provided by Celldex Therapeutics,
at 4uC overnight. After blocking with BSA and several wash steps,
conditioned media from BT549 cells was allowed to adhere to the
antibody-coated plate for one hour at 37uC. A goat anti-GPNMB/
OA antibody (R&D systems, Minneapolis, MN) was used as a
detection antibody and an HRP-conjugated donkey anti-goat
antibody (Jackson ImmunoResearch Laboratories) in concert with
TMB (3,39,5,59-tetramethylbenzidine) chromogenic substrate
(Pierce Thermoscientific, Rockford, IL) was used to visualize the
reaction. Plates were quantified with 540/450 nm wavelength
readings on a Bio-Plex Reader (Bio-Rad Laboratories, Hercules,
CA) and data was analyzed with Bio-Plex Manager 2.0 software
(Bio-Rad Laboratories, Hercules, CA). Soluble VEGF was
quantified using manufacturer’s protocol with a commercially
available ELISA kit (R&D systems, Minneapolis, MN).
Endothelial migration assays
For assessing endothelial migration, a GPNMB-specific ELISA
was used to quantify the amount of GPNMB/OA sECD present in
the CM of GPNMB/OA-expressing BT549 cells that had been
cultured for two days in serum free media. A volume of media
containing 50ng of the sECD was added to a final volume of 1 mL
of serum-free media and placed in the bottom chamber of a
modified Boyden chamber assay. The same volume of concen-
trated conditioned media was added from the vector control cells.
Untreated refers to serum free media (SFM) that was not mixed
with conditioned media harvested from GPNMB/OA-expressing
or vector control cells. Briefly, 7.5610
4 HPMECs were seeded in
the upper well and allowed to migrate through an 8mm porous
membrane towards the conditioned media in the bottom chamber
for a period of 18 hours. For EC migration experiments
employing recombinant factors, recombinant FGF2 (50 ng/ml;
BPS Bioscience, San Diego, CA), VEGF (50 ng/ml; BPS
Bioscience, San Diego, CA) and GPNMB/OA (rhECD, 100ng/
ml; Celldex, Needham, MA) was added to 1mL SFM in the
bottom chamber, and 1610
5 HPMECs were plated in the upper
chamber and allowed to migrate through the filter for a period of
18 hours. At the termination of each experiment, cells were fixed
in formalin, stained with crystal violet (Sigma) and those cells
remaining on the upper side of the membrane were removed by
scraping. Five images were taken for each insert and the cells were
quantified using Scion Image software (Scion Corporation). Data
for each insert are represented as the average pixel count from the
five images. The data was obtained from at least three
independent experiments, performed in triplicate wells.
Supporting Information
Figure S1 Tumors derived from a pool of GPNMB/OA
expressing 66cl4 cells display enhanced tumor outgrowth in
immunocompetent Balb/c and athymic mice. (A) GPNMB/OA
expression was confirmed by immunoblot analysis of total cell
lysates from pooled vector control (VC) and GPNMB/OA-
expressing (GPNMB/OA pool) 66cl4 cells. As a loading control,
total cell lysates were blotted for a-Tubulin. (B) Tumor growth
curves from Balb/c (triangles) and athymic (circles) mice injected
with 16105 VC (open symbols) or GPNMB/OA pool (filled
symbols) expressing 66cl4 cells. *, P=0.0003, GPNMB/OA pool
(athymic) vs. VC (athymic); **, P,0.0001, GPNMB/OA pool
(Balb/c) vs. VC (Balb/c); #, P=0.0001, GPNMB/OA (Balb/c)
vs. GPNMB/OA (athymic). All P-values were determined using a
non-parametric Mann-Whitney test for serial measurements.
Found at: doi:10.1371/journal.pone.0012093.s001 (0.65 MB TIF)
Figure S2 Analysis of VEGF expression and endothelial
recruitment in breast cancer cells expressing GPNMB/OA. (A)
Total cell lysates and (B) cell supernatants were extracted from
vector control (VC, black bars) and GPNMB/OA-expressing
(GPNMB/OA4, blue bars) 66cl4 cells grown in vitro and from (C)
tumors grown in vivo. Tumors were excised at a volume of 200–
300mm3 and flash frozen in liquid nitrogen. VEGF protein was
quantified using ELISA and normalized to the total amount of
protein in the corresponding cell lysate (A, B) or tumor lysates (C).
*, P=0.003, Students t-test.
Found at: doi:10.1371/journal.pone.0012093.s002 (0.52 MB TIF)
Figure S3 GPNMB/OA promotes angiogenesis in an in vivo
human breast cancer model. VC or GPNMB/OA-expressing
BT549 cells (16106) were suspended in a 50:50 solution of
PBS:matrigel and injected subcutaneously into athymic mice and
the animals sacrificed 10 days later. (A) CD31 (endothelial
marker)-stained pixels were quantified for each matrigel plug
and normalized to the number of total nuclei in the section. *,
P=0.021, Students t-test. (B) Vasculature recruited into the
matrigel plugs was visualized on the inner surface of the skin
(upper panels). Representative images of CD31 stains are shown
(lower panels). Scale bars represent 100 mm.
Found at: doi:10.1371/journal.pone.0012093.s003 (1.96 MB TIF)
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